Financial release accessible onlineBOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information: Tele ...

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, ...

Haemonetics (HAE) recently completed the sale of its whole blood assets to GVS, S.p.A ("GVS"), a leading provider of advanced filtration solutions for highly critical applications. With this development, GVS now has the company’s portfolio of proprietary whole blood collection, processing and filtration solutions, along with its manufacturing facility in Covina, CA and related equipment and assets at its Tijuana, Mexico manufacturing site.The transaction was announced last month and comprises a total cash c ...

BOSTON, Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced that it has completed the previously announced sale of its whole blood assets to GVS, S.p.A ("GVS"), one of the world's leading manufacturers of filter solutions for applications in the healthcare and life sciences sectors. In connection with the closing of this transaction, GVS has acquired Haemone ...

BOSTON, Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, February 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 6, 2025. The call can be accessed via teleconference at: Q3 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will ...

BOSTON, Jan. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025 at 5:15 pm Pacific Time.The public may access Mr. Simon's presentation live via audio webcast at: https://jpmorgan.metameetings.net/events/healthcare25/sessions/58190-haemonetics-corporation/webcast?gpu_only=true&kiosk=true  The live webcast can also be accessed under the Events ...

Core Viewpoint - Haemonetics Corporation has experienced a decline in share price over the past year, losing 12.3% compared to the industry's growth of 11.2% and the S&P 500's rise of 25.7% [1] Company Performance - The consensus estimate for Haemonetics' fiscal 2025 revenues is projected at $1.39 billion, reflecting a 6.2% increase from the previous year [8] - The company has a market capitalization of $3.88 billion and has beaten earnings estimates in three of the last four quarters, with an average surprise of 2.82% [12][16] Key Upsides - The NexSys PCS system, which is FDA-cleared, is designed to enhance plasma yield collections, improve productivity, and provide a better donor experience, with the proprietary Persona Technology increasing yield by 9-12% on average [3][6] - Haemonetics plans to upgrade all remaining NexSys customers to Express Plus and Persona by the end of fiscal 2025, aiming to capture more market share domestically and internationally [6] Key Downsides - Despite strong growth potential from the Plasma franchise and robust uptake of the NexSys PCS system, Haemonetics faces challenges from intense competition in the market [4][15] Financial Stability - The company exited the second quarter of fiscal 2025 with $299.3 million in cash and cash equivalents, indicating strong solvency, although the current ratio decreased to 3.49% from 3.76% in the previous quarter [14] Competitive Landscape - Haemonetics operates in a highly competitive environment for both manual and automated systems, with potential revenue impacts from slower-than-expected product adoption, particularly from key customers like the American Red Cross [15]

Haemonetics (HAE) has been on a downward spiral lately with significant selling pressure. After declining 11.8% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock i ...

Core Insights - The article compares Haemonetics (HAE) and Stryker (SYK) to determine which stock presents a better value opportunity for investors [1] Valuation Metrics - Haemonetics has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision trend compared to Stryker, which has a Zacks Rank of 3 (Hold) [3] - HAE's forward P/E ratio is 17.88, significantly lower than SYK's forward P/E of 30.75, suggesting HAE may be undervalued [5] - The PEG ratio for HAE is 1.27, while SYK's PEG ratio is 2.80, indicating HAE's expected earnings growth is more favorable relative to its price [5] - HAE's P/B ratio stands at 4.78, compared to SYK's P/B of 7.02, further supporting HAE's valuation as more attractive [6] Value Grades - HAE has a Value grade of B, while SYK has a Value grade of C, indicating that HAE is perceived as a better value investment at this time [7]

If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 yearsMARBURG, Germany, Dec. 13, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorization for garadacimab as a once-monthly p ...